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Amylin (islet amyloid peptide) plays a critical role in islet
amyloidosis and in the development of b-cell dysfunction in
patients with diabetes; however, the involvement of amylin
in renal amyloidosis has not been studied. For this reason, we
surveyed 149 patients with biopsy-proven diabetic
nephropathy (DN). The results were compared to 95 renal
disease control patients, which included
membranoproliferative glomerulonephritis, light-chain
deposition, IgA nephropathy, and obesity-related
glomerulopathy (ORG). Seventy-two of the 149 patients with
DN showed amylin deposition in their renal tissue. Amylin
was mainly distributed in the expanded mesangial area,
Kimmelstiel–Wilson nodules, Bowman’s capsule, and in blood
vessels. The frequencies of mesangial proliferation,
glomerular nodule lesions, and glomerular sclerosis were
higher in DN patients with amylin deposits. Furthermore, the
tubular interstitial lesions were more severe in these patients.
Of the 95 disease-control patients, four with ORG were
positive for renal amylin deposits. Our study has found renal
amylin deposition in patients with DN and that the
deposition was associated with disease severity. We suggest
that strict metabolic control and reversing insulin resistance
in patients with diabetes may blunt the process of amylin
deposition in the kidney and possibly protect renal function
in these patients.
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Insulin resistance and islet b-cell dysfunction are two key
events in the development of type II diabetes mellitus (DM).
Islet amyloidosis is a major cause of islet b-cell dysfunction
and was found in 70–90% of patients with type II DM at
autopsy.1–3 It was found that the amyloid fibrils, deposited in
the pancreatic islets are composed of islet amyloid polypep-
tide, also known as amylin.4–6 As amylin and insulin share
common promoter elements, hyperinsulinemia inevitably
accompanies by hyperamylinemia. Actually, plasma amylin
level is elevated in the type II diabetic patients7 and
immunoreactive amylin is present in the urine of these
patients.8
The cytotoxic effects of amylin to b-cell within the islet
were well documented. The islet amylin fibril deposition is
associated with 40–50% decreased b-cell mass and b-cell
dysfunction.2,3,9–11 In addition to the direct effects of amylin
on islet b-cell,12 amylin aggregation may also participate in
stimulating lipolysis, elevating plasma free fatty acid level,7
activating the renin angiotensin aldosterone system,13
stimulating advanced glycosylation endproducts (AGEs)
receptors, and promoting inflammatory process7,13 in
patients with diabetes.
The characteristic pathological changes of diabetic ne-
phropathy (DN), such as glomerular mesangial matrix
expansion, glomerular basement membrane thickness and
the Kimmelstiel–Wilson (K-W) nodules formation, indicate
abnormal accumulation of extracellular matrix. Some
pathogenic molecules may contribute to the formation of
these lesions. As a kind of amyloid protein, amylin can form
b-sheet structure and deposit in the tissue. We know that
kidney is the most common involved organ in systemic
amyloidosis. It is rational to assume that amylin may deposit
in the renal tissue in patients with hyperamylinemia and
abnormal glucose metabolism. Here, we first describe the
renal amylin deposition and its role in renal tissue damage in
patients with DN.
RESULTS
Amylin deposition in the renal tissue of patients with DN
Amylin deposition was found in 72 of 149 patients (48.3%)
with DN. Amylin mainly distributed in the expanded
mesangial area, K-W nodules, the Bowman’s capsule,
interstitium as well as the blood vessels (Figure 1a–d). The
amylin staining in normal pancreatic tissues of patients
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showed positive (Figure 1e). The renal amylin staining in five
normal controls showed negative (Figure 1f).
To further confirm the specialty of renal amylin deposition
in patients with DN, several kinds of controls were designed
for this purpose. Glomerular nodular lesion: patients with
membranoproliferative glomerulonephritis (MPGN, n¼ 18)
and patients with light-chain deposition disease (LCDD,
n¼ 15); glomerular mesangial proliferative lesion: patients
with IgA nephropathy (IgAN, n¼ 30); Patients with meta-
bolic disorder: obesity-related glomerulopathy (ORG,
n¼ 32). There was no amylin deposition in the renal tissue
of patients with MPGN, LCDD, and IgAN. Interestingly, four
(12.5%) out of 32 ORG patients showed amylin deposition in
the renal tissue. Amylin distributed in glomerular mesangial
area, Bowman’s capsule, and blood vessels (Table 1).
Comparison of renal pathological changes in DN patients
with or without amylin deposition
It was found that the frequency of diffuse mesangial
proliferation was higher in patients with amylin deposition
as compared to patients without amylin deposition (75 vs
48.6%, Po0.005). Both the glomerular nodular lesions and
glomerular sclerosis proportion (415%) were also higher in
patients with amylin deposition than those without amylin
deposition. And also the tubular interstitial lesions were more
severe in patients with amylin deposition (Table 2).
Ultrastructure characteristic of amylin in the renal tissue
The fibril deposits were found in the mesangium of DN
patients with glomerular positive amylin staining. The
appearance of fibrils showed to be straight, long, and non-
branching with a diameter of 12–16 nm. In most cases, the
fibrils were randomly arranged in the mesangium and in the
glomerular basement membrane. But some deposits were
seen in a tightly packed, parallel arrangement (Figure 2a).
Immunogold electron microscopy (EM) with an antibody
to the amylin revealed the gold particles in the fibrils
(Figure 2b).
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Figure 1 | Amylin deposition in the renal tissue of patients with
DN. Amylin deposit was observed in the (a) expanded mesangial
area, (b) glomerular segmental sclerosis, (c) K-W nodular lesion, and
(d) the blood vessel. The renal amylin staining showed (e) positive in
normal pancreatic tissues and (f) negative in normal control (original
magnification  400).
Table 1 | Renal amylin deposition in patients with DN and
other relevant diseases
DN MPGN LCDD IgAN ORG
n 149 18 15 30 32
Amylin deposition 72 (48.3%) 0 0 0 4 (12.5%)
Glomeruli P N N N P
Blood vessels P N N N P
Interstitium P N N N P
DN, diabetic nephropathy; IgAN, IgA nephropathy; LCDD, light-chain deposition
disease; MPGN, membranoproliferative glomerulonephritis; N, negative; ORG,
obesity-related glomerulopathy; P, positive.
Table 2 | Comparison of renal pathological changes in
patients with or without amylin deposition
Amylin deposition
Positive (%) Negative (%) P-value
n 72 77
Glomerular lesions
Diffuse mesangial proliferation 54 (75.0) 35 (48.6) o0.005
Nodular lesions 52 (72.2) 32 (41.6) o0.005
Glomerulose lesions (415%) 49 (68.1) 33 (45.8) o0.005
Tubular-interstitial lesions
Mild 7 (9.7) 34 (44.2) o0.005
Moderate 35 (48.6) 33 (42.9) 40.05
Severe 30 (41.7) 10 (13.0) o0.005
a
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Figure 2 | Ultrastructure characteristic of amylin in the renal
tissue of patients with DN. (a) The fibril deposits were found in the
mesangium of DN patients with glomerular positive amylin staining.
(b) Immunogold EM with an antibody to the amylin revealed the gold
particles in the fibrils.
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Comparison of plasma amylin level in DN patients with
or without amylin deposition
The fasting plasma amylin level was detected in patients with
amylin deposition (n¼ 18), patients without amylin deposi-
tion (n¼ 34), and the age/sex matching normal controls
(n¼ 17). The results were 31.0715.2, 30.5710.1, and
21.374.6 pmol/l, respectively. The plasma amylin level was
significantly higher in patients with DN than normal controls
(Po0.01). But there were no statistical difference between
DN patients with or without amylin deposition. The fasting
plasma amylin level of 11 ORG patients were
26.1374.86 pmol/l. It was higher than normal controls
(Po0.05) but lower than DN patients (Po0.05).
Comparison of clinical manifestations in DN patients with
or without amylin deposition
There were no significant differences in the levels of fasting
glucose, postprandial glucose, glycated hemoglobin, trigly-
cerides, and cholesterol between patients with or without
amylin deposition. The fasting and postprandial insulin levels
were higher in patients with amylin deposition than those
without amylin deposition, but did not achieve statistical
difference. The body mass index was lower in patients with
amylin deposition (Po0.05) (Table 3).
The proteinuria and serum creatinine levels were sig-
nificantly higher in patients with amylin deposition
(Po0.01), and their serum albumin level, glomerular
filtration rate, and hemoglobin level were much lower than
patients without amylin deposition (Po0.01). Much more
severe renal tubular interstitial lesions were observed in
patients with amylin deposition, and they have higher urine
N-acetyl-beta-glucosaminidase (Po0.01) and lower urine
osmolarity (Po0.01) than patients without amylin deposi-
tion (Table 3).
DISCUSSION
Amylin, a kind of amyloid protein, may form b-sheet
structure and deposit in the tissues.14 It has been well
documented that islet amyloid has been demonstrated in up
to 90% of individuals with type II DM and the degree of
pancreatic amyloidosis paralleled with the severity of the
disease.4 Islet deposition of amylin may induce b-cell damage
and apoptosis to result in b-cell dysfunction and absolute loss
of b-cell mass by direct oxidation, special calcium channel
formation on cell membrane,15 and increased expression of
p53 and p21 in the b-cell.16 Insulin resistance and reduced b-
cell mass induced by amylin result in hyperglycemia and will
further stimulate compensatory secretion of insulin and
amylin in remanent b-cells. Then hyperamylinemia turned
back aggravating insulin resistance and b-cell dysfunction.
This vicious circle leads to b-cell failure and accelerate
the progression of diabetes. Transgenic mice expressing
human amylin spontaneously exhibit a diabetic phenotype,
such as obesity, hyperglycemia, and hyperinsulinemia.17 This
Table 3 | Comparison of the clinical manifestations in patients with or without amylin deposition
Amylin deposition
Positive Negative P-value
n 72 77
Gender (male/female) 48/24 48/29 40.05
Age (years) 51.3679.45 52.36710.54 0.543
Initial age (years) 41.9079.80 44.7179.55 0.078
Duration of DM (months) 108.74775.62 90.12770.27 0.121
Duration of DN (months) 23.24726.87 17.73721.84 0.171
BMI 24.5974.00 25.9573.57 0.031
Fasting blood glucose (mmol/l) 6.7972.69 7.1172.38 0.439
Postprandial blood insulin (mmol/l) 12.9275.06 11.9674.22 0.241
Fasting blood insulin (mIU/l) 24.01725.85 19.47715.89 0.244
Postprandial blood insulin (mIU/l) 55.44739.19 46.50727.27 0.321
Glycated hemoglobin (%) 6.6671.33 6.9871.38 0.177
Serum albumin (g/l) 33.9577.91 37.7977.15 0.002
Serum globulin (g/l) 24.1774.24 24.7973.70 0.348
Serum cholesterol (mmol/l) 5.7371.70 5.6972.51 0.906
Serum triglyceride (mmol/l) 2.2671.66 2.4973.37 0.600
Serum HDL-c (mmol/l) 1.3670.49 1.2570.36 0.149
Serum LDL-c (mmol/l) 3.1971.28 3.4471.39 0.318
Hypertension N (%) 70 (97.2%) 63 (81.8%) o0.005
Blood urea nitrogen (mg/dl) 23.23716.17 16.24710.03 0.002
Serum creatinine (mg/dl) 1.9971.63 1.1670.80 o0.001
GFR (ml/min) 52.99730.44 74.24730.13 0.001
Proteinuria (g/24 h) 4.0272.55 2.6273.35 0.005
Urine NAG enzyme (l/g Cr) 40.72734.58 30.08726.31 0.035
Urine retinol binding protein (mg/l) 6.1178.37 3.3778.35 0.066
Urinary osmotic pressure (mosM/kg H2O) 442.937140.30 594.757211.94 o0.001
Hemoglobin (g/dl) 10.7972.56 12.5972.27 o0.001
BMI, body mass index; DM, diabetes mellitus; DN, diabetic nephropathy; HDL-c, high-density lipoprotein-c; LDL-c, low-density lipoprotein-c; NAG, N-acetyl-beta-
glucosaminidase. We use bold characters to outline the items which have statistical significance.
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indicates that exceeding physiological concentration of
amylin participate in the formation of diabetes.
As amylin plays so important role in the insulin resistance
and diabetic-associated tissue injury, the role of amylin in
diabetic renal lesions should not be ignored. Our results first
indicated that 48.3% of patients with DN have renal amylin
deposition. The specialty meaning of amylin deposition
found in DN patients was confirmed by the disease controls.
Amylin was not found in the renal tissue of patients with
MPGN, LCDD, and IgAN. The renal amylin deposition
mainly distributed in expanded mesangial area, K-W
nodules, thickened Bowman’s capsule, and injured blood
vessel wall in patients with DN. And this kind of distribution
was corresponding to characteristic renal lesions in DN. For
instance, the frequency of glomerular nodular lesions,
glomerulosclerosis, and the degree of tubular interstitial
lesions are more severe in patients with amylin deposition
than patients without renal amylin deposition. Consistent to
these, the 24-h urine protein excretion, urinary N-acetyl-
beta-glucosaminidase level, blood pressure, and serum
creatinine level were elevated significantly in patients with
renal amylin deposition. Furthermore, the glomerular filtra-
tion rate as well as hemoglobin level was markedly decreased
in patients with amylin deposition. These findings indicate
that renal amylin deposition may participate the process of
diabetic renal lesion.
Exogenously added human amylin is cytotoxic and
induces apoptosis when added to a variety of cultured cells,
including primary rat pancreatic cells, hippocampal neurons,
aortic endothelial cells, PC12 pheochromocytoma cells,18 and
COS cells.19 To explore the underlying mechanisms of amylin
deposition-induced renal tissue injury in patients with DN,
other previous studies demonstrated that amylin is able to
induce mesangial cell apoptosis and increase the permeability
of endothelial cells in vitro.20 These effects may contribute to
the renal damage mediated by amylin deposition in patients
with DN. Also Cooper and co-workers had demonstrated
that amylin intermediates rather than amylin-associated
amyloid are more responsible for b-cell toxicity.21 So amylin
oligomers may be more toxic than amyloid itself in diabetic
renal lesion. In addition, amylin may deposit in renal tissue
by binding with its corresponding receptor. The known
amylin receptor-like molecules include receptor for advance
glycosylation endproducts (RAGEs)22 and calcitonin recep-
tor.23 As RAGE was expressed in the glomerular visceral
epithelial cells (podocytes),24 it is assumed that amylin may
bind with RAGE on podocytes. RAGE was activated when
binding with its ligand – amylin. Then several signal-
transduction pathways involved in inflammation were
activated, such as P21 Ras, mitogen-activated protein kinase,
nuclear factor-kB, and CDC42/rac pathway.25 Activation of
RAGE may induce vascular endothelial growth factor
expression, which may induce vascular endothelial cell
hyperpermeability, upregulate intracellular adhesion mole-
cule-1 expression, promote adhesion and inflammation of
macrophage cells, activate nuclear factor-kB, and increase the
secretion of proinflammatory factors such as tumor necrosis
factor-a, interleukin-1b, and interleukin-626 and involved in
the podocyte injury and the development of proteinuria. Of
course, this needs to be clarified. It has been reported that
renal amylin deposition can trigger the activation of renin
angiotensin aldosterone system. Wookey et al.27 demon-
strated that there was a significant correlation between the
increased density of amylin binding sites in the renal cortex
and the rise of systolic blood pressure in two animal models
of hypertension. The higher frequency of hypertension on
patients with amylin deposition found in this study supports
the correlation between renal amylin deposition and
increased blood pressure.
It has been revealed that the increased secretion of amylin
and elevated circulating amylin concentration will promote
the formation of pancreatic islet amylin deposition.28,29 To
answer why only a part of DN patients showed amylin
deposition in the renal tissue, the plasma amylin concentra-
tion was measured in these patients. The plasma amylin
concentration was significantly higher in patients with DN
than normal controls. However, no difference was found
between DN patients with or without renal amylin deposi-
tion. This result indicated that increased plasma amylin
concentration is necessary but not the only factor that
determines the renal amylin deposition. In the state of DM,
hyperglycemia and hyperlipidemia-induced glycotoxicity,
lipotoxicity, and redox stress may promote and accelerate
islet amyloid formation. AGEs may modify amylin protein
structure squinting toward crosslink and assembly in
post-transcription mode and accelerate the islet amyloid
deposition.30,31 Thus, comparison was made in the abnorm-
alities of glucose and lipid metabolism between DN patients
with or without renal amylin deposition. Although there
were no difference found between them. The therapeutic
intervention in these patients could not been ruled out.
Note that, four out of 32 patients with ORG showed renal
amylin deposition further illustrate the correlation between
metabolic disorders and renal amylin deposition. Insulin
resistance is a common metabolic disorder in patients with
ORG,7 the elevated plasma amylin level found in this group
of ORG patients not only indicate the presence of insulin
resistance in these patients, but also demonstrate the
correlation between the metabolic disorder and the deposi-
tion of amylin in the renal tissue, and may extend this issue
to renal protection in patients with ORG or metabolic
syndrome.
We first time described that renal amylin deposition was
found in patients with DN, and the deposition associated
with the disease severity. In addition to the hyperamylinemia,
the metabolic disorders and the change of local milieu of
kidney may accelerate the formation of amylin deposition in
the renal tissue. Although further studies are needed to
explore the pathogenetic role of amylin in the development of
diabetic renal lesions, the finding of this study indicates that
strict metabolic control and reversing the state of insulin
resistance in patients with diabetes may blunt the process of
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amylin deposition and protect renal function in these
patients.
MATERIALS AND METHODS
Patients
One hundred and forty-nine patients with biopsy-proven type II DN
were selected in this study. There were 96 male and 53 female patients,
age ranged from 29 to 74 years old (51.88710.01 years). All these
patients met the criteria for type II DM, and the renal biopsy
consistent with the diagnosis of DN and exclusion for other
concomitant renal diseases. The patients’ hospital records, including
age, gender, course of disease, stature, avoirdupois, blood pressure, the
level of fasting and postprandial blood glucose, fasting and
postprandial blood insulin, glycated hemoglobin, serum albumin,
globulin, cholesterol, triglyceride, high-density lipoprotein-c,
low-density lipoprotein-c, blood urea nitrogen, serum creatinine,
hemoglobin, glomerular filtration rate, proteinuria, urine N-acetyl-
beta-glucosaminidase enzyme, urine retinal binding protein, and
urinary osmotic pressure were obtained. The disease controls used in
this study include MPGN (n¼ 18), LCDD (n¼ 15), IgAN (n¼ 30),
and ORG (n¼ 32). Here, patients with ORG were defined as obesity
(body mass index of 28 kg/m2 or greater), proteinuria, and biopsy-
proven ORG. Patients with MPGN, LCDD, and IgAN have normal
body mass index and normal glucose metabolism. Six normal donor
kidneys unfitting for transplantation served as normal controls. Five
normal pancreatic tissues of patients obtained in surgery served as
positive controls.
Renal histology
Renal specimens were fixed in 10% neutrally buffered formalin and
embedded in paraffin using routine procedures. Sections (2 mm in
thickness) were stained with hematoxylin/eosin, periodic acid-Schiff
reagent, silver methenamine, and Ledewig’s trichrome. Alkaline
Congo Red staining was performed in five pancreatic tissues of
patients with type II DM. Renal histological changes were recorded
by the same pathologist in single-blind mode. Here, the mild
interstitial lesions defined as accounting for less than 25% area of
interstitium. The moderate interstitial lesions defined as among
26–50% area of interstitium. The severe interstitial lesions defined as
more than 50% area of interstitium.32
Immunohistochemistry staining of amylin in renal tissue
Cryosections (4mm) were prepared and fixed for 7 min in acetone. To
observe the distribution of amylin in renal tissues, peroxidase-
antiperoxidase (PAP) four-layer staining protocol was performed.
Briefly, after incubation with 10% fetal calf serum for 20 min to block
unspecific binding, the primary antibody (monoclonal antibody to
amylin, 1:50, Serotec, Washington, DC, USA) was applied for
overnight at 41C, followed by a sequential incubation with horse-
radish peroxidase-conjugated secondary antibody (rabbit anti-mouse
IgG, 1:100, Dako, Carpinteria, CA, USA), bridging antibody (swine
anti-rabbit IgG, 1:100, Dako), and rabbit PAP (1:100, Dako) for
40 min each at room temperature. Sections were then visualized using
3,30-diamino-benzidine and counter-stained with hematoxylin, dehy-
drated, and mounted with neutral resin. Negative controls were
performed by replacing the primary antibody with isotype control
and by disusing the treatment of the first antibody.
Measurement of fasting plasma amylin level
The plasma amylin level was measured with competitive enzyme-
linked immunosorbent assay (Phoenix pharmaceutical, INS,
Burlingame, CA, USA) according to the manufacturer’s protocol.
Five milliliters blood samples was collected from each patient and
was put into the lavender vacutaner tubes that containing
ethylenediaminetetraacetic acid. Then the tubes were gently rocked
several times immediately after collection of blood with anti-
coagulation. The blood samples were transferred from the lavender
vacutaner tubes to centrifuge tubes containing aprotinin (0.6 TIU
(trypsin inhibitor unit)/ml of blood, Calbiochem, San Diego, CA,
USA) and gently rocked for several times. The blood samples were
centrifuged at 1600 g for 15 min at 41C and the plasma collected.
Then the plasmas were acidified with an equal amount of buffer A
(1% trifluoroacetic acid), mixed, and centrifuged at 10 000 g for
20 min at 41C. A SEP-COLUMN containing 200 mg of C18 (Phoenix
pharmaceutical) was equilibrated by washing the buffer B (60%
acetonitrile in 1% trifluoroacetic acid) (1 ml, once) followed by
buffer A (3 ml, three times). The acidified plasma solutions were
loaded onto the pretreated C18 SEP-COLUMN. The column was
washed slowly with buffer A (3 ml, twice) and the wash was
discarded. The peptide was eluted slowly with buffer B (3 ml, once)
and eluant was collected into a polystyrene tube. Eluant was
evaporated to dryness and kept at 201C. The dried extract was
reconstituted by assay buffer. Fifty microliters prepared peptide
standard solutions or blood samples, 25 ml rehydrated primary
antiserum, and 25 ml rehydrated biotinylated peptide were added
into their designated wells. And the immunoplate was incubated for
2 h at room temperature. Each well was washed with 300 ml assay
buffer for five times. Hundred microliters streptavidin-horseradish
peroxidase solution was added into each well and incubated for 1 h
at room temperature. The immunoplate was washed and blot dried
six times. Then 100ml substrate solution provided in the kit was
added into each well and incubated for 1 h at room temperature.
Hundred microliters 2 N HCl was added into each well to stop the
reaction. Absorbance optical density (OD) at 450 nm was read and
calculated. The concentration of amylin was calculated as pmol/l.
Electron microscopy and immunogold electron microscopy
The ultrastructure was evaluated using EM. Briefly, renal tissue
fragments were fixed in a cool 3.75% phosphate-buffered glutar-
aldehyde solution (0.2 M, pH 7.2), post-fixed in 1% osmium
tetroxide, and embedded in epon. Ultrathin sections were observed
and microphotographs were obtained using EM (HITACHI 7500,
Tokyo, Japan).
Immunogold EM was used to find amylin deposition in renal
tissue. Small renal pieces were fixed in 1% paraformaldehyde in
phosphate-buffered saline (PBS) for 4 h and subsequently washed in
PBS, then dehydrated in graded ethanols and embedded in LR White
resin. Semithin sections (1 mm) were cut from epon-embedded
blocks and stained with toluidine blue. Ultrathin sections (80 nm)
were cut in an ultratome (Leico EM UC6), mounted on nickel grids,
blocked with 2% bovine serum albumin in PBS for 10 min, and
incubated with mouse anti-human amylin (Serotec, catalog number
MCA1126) diluted 1:20 in 1% bovine serum albumin for overnight
at 41C. The grids were washed in PBS for 10 times and then
incubated with 2% bovine serum albumin for 10 min. After
discarding the liquid followed by goat anti-mouse IgG coupled to
10-nm colloidal gold (catalog number 25129, Electron Microscopy
Science, Fort Washington, PA, USA), control grids were incubated
with PBS substitute for mouse-anti-human amylin and by disusing
the treatment of mouse-anti-human amylin. Then, grids were
stained with uranyl acetate (25 min) and lead citrate (12 min) and
examined with EM (HITACHI 7500, Tokyo, Japan).
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Statistical analysis
Statistical analyses were performed using SPSS software (version
11.0). Data were expressed as mean7s.d. and analyzed using the
one-way analysis of variance and Student’s t-test. Statistical
significance was assumed for Po0.05 and very high significance
levels were defined as Po0.01.
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